Table 1.
Demographic and General Cognition Characteristics Between PD Cognitive Phenotypes and Non-PD Peers
| Variable | PD Executive (n=25) | PD Memory (n=35) | PD Cognitively Well (n=56) | Non-PD (n=65) | p-value |
|---|---|---|---|---|---|
| Gender (M:F) | 19:6 | 27:8 | 37:19 | 48:17 | .63 |
| Age (yrs) | 69.08±6.30, 55/81 | 66.48±6.19, 55/84 | 68.84±6.01, 56/82 | 68.23±5.4, 55/80 | .25 |
| Education (yrs) | 15.58±2.37, 12/21 | 16.06±2.37, 10/20 | 17.11±2.71, 11/23 | 17.19±2.23, 12/22 | .02* |
| Handedness | 20.20±4.53 | 21.46±3.18 | 19.75±5.45 | 20.88±4.84 | .35 |
| Disease Duration (yrs) | 8.92±6.89, 1/26 | 5.74±3.22, 1/12 | 6.64±4.33, 1/23 | -- | .04 |
| UPDRS III | 22.84±9.31, 5/44 | 22.36±11.26, 4/57 | 18.45±10.70, 2/46 | 4.13±4.62, 0/18 | .08** |
| l-Dopa Equiv. Score | 665.95±371.29, 0/1232 | 648.83±416.57, 0/1800 | 661.55±277.12, 100/1450 | -- | .98 |
| Magellan Score | 0.81±1.39, 0/6 | 0.76±1.15, 0/3 | 0.89±1.15, 0/4 | 0.25±0.82, 0/5 | <.01 |
| Charlson Comorbidity Index | 0.33±0.57, 0/2 | 0.17±0.38, 0/1 | 0.44±0.76, 0/4 | 0.33±0.66, 0/2 | .34 |
| MMSE Total | 28.16±1.57, 24/30 | 28.20±1.49, 24/30 | 28.95±1.00, 26/30 | 29.20±0.98, 25/30 | <.01 |
| BDI-II* | 11.00±5.64, 3/23 | 8.11±5.64, 0/28 | 7.46±5.75, 0/24 | 3.12±4.63, 0/27 | <.01* |
| Apathy Scale | 13.09±5.94, 4/26 | 9.43±5.42, 2/26 | 9.80±5.80, 0/24 | 9.35±4.87, 1/30 | .03* |
This sample represents Caucasian non-Hispanic individuals within Florida, United States, at time of study. All values presented as Mean±SD, Min/Max. p-value represents overall between group (PD Executive, PD Memory, PD Well, Non-PD) comparison difference;
indicates significant difference between PD phenotypes.
p-value when comparing PD phenotypes only. Apathy scale[32]; BDI-II = Beck Depression Inventory-2[30]; Handedness = Modification of Annette (1976) inventory with range −24 to 24 (higher positive = right-side dominance; [26]; l-Dopa Equiv. Score = Levodopa Equivalent Sore = Total Daily levodopa dosage intake in milligrams[28]; MMSE = Mini-Mental State Exam[29]; UPDRS III = United Parkinson’s Disease Rating Scale III [33].